The Medical Letter on Drugs and Therapeutics
Recombinant Human Parathyroid Hormone (Natpara)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a subcutaneously injected formulation of recombinant human parathyroid hormone (Natpara – NPS) as an adjunct to calcium and vitamin D to control hypocalcemia in adults with hypoparathyroidism. Natpara is an 84-amino acid single-chain polypeptide identical to native parathyroid hormone. It is the first parathyroid hormone formulation to be approved for this indication.

PARATHYROID HORMONE — Secreted in response to low serum calcium, parathyroid hormone binds to PTH-1 receptors both in bone, causing release of calcium into blood, and in the kidneys, increasing tubular reabsorption of calcium and conversion of vitamin D to its most active form.1

TREATMENT OF HYPOPARATHYROIDISM — Hypocalcemia caused by hypoparathyroidism is usually managed with oral calcium and vitamin D. Patients typically require at least 1-2 g/day ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Recombinant Human Parathyroid Hormone (Natpara)
Article code: 1470c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian